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Background. The muscle glycogen synthase gene (GYS1) has been associated with type 2 diabetes (T2D), the metabolic
syndrome (MetS), male myocardial infarction and a defective increase in muscle glycogen synthase protein in response to
exercise. We addressed the questions whether polymorphism in GYS1 can predict cardiovascular (CV) mortality in a high-risk
population, if this risk is influenced by gender or physical activity, and if the association is independent of genetic variation in
nearby apolipoprotein E gene (APOE). Methodology/Principal Findings. Polymorphisms in GYS1 (XbaIC.T) and APOE (-
219G.T, e2/e3/e4) were genotyped in 4,654 subjects participating in the Botnia T2D-family study and followed for a median of
eight years. Mortality analyses were performed using Cox proportional-hazards regression. During the follow-up period, 749
individuals died, 409 due to CV causes. In males the GYS1 XbaI T-allele (hazard ratio (HR) 1.9 [1.2–2.9]), T2D (2.5 [1.7–3.8]),
earlier CV events (1.7 [1.2–2.5]), physical inactivity (1.9 [1.2–2.9]) and smoking (1.5 [1.0–2.3]) predicted CV mortality. The GYS1
XbaI T-allele predicted CV mortality particularly in physically active males (HR 1.7 [1.3–2.0]). Association of GYS1 with CV
mortality was independent of APOE (219TT/e4), which by its own exerted an effect on CV mortality risk in females (2.9 [1.9–
4.4]). Other independent predictors of CV mortality in females were fasting plasma glucose (1.2 [1.1–1.2]), high body mass
index (BMI) (1.0 [1.0–1.1]), hypertension (1.9 [1.2–3.1]), earlier CV events (1.9 [1.3–2.8]) and physical inactivity (1.9 [1.2–2.8]).
Conclusions/Significance. Polymorphisms in GYS1 and APOE predict CV mortality in T2D families in a gender-specific fashion
and independently of each other. Physical exercise seems to unmask the effect associated with the GYS1 polymorphism,
rendering carriers of the variant allele less susceptible to the protective effect of exercise on the risk of CV death, which finding
could be compatible with a previous demonstration of defective increase in the glycogen synthase protein in carriers of this
polymorphism.
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INTRODUCTION
Cardiovascular (CV) disease (CVD), including coronary heart
disease (CHD) and stroke, is the leading cause of death and
disability in the Western world [1] and is thought to result from
a complex interaction between genetic and environmental factors.
Such risk factors are age, male gender, smoking, hypertension,
diabetes, dyslipidemia [2] and physical inactivity. The genetic
constitution of an individual usually determines how the individual
responds to these risk factors. Therefore, it is necessary not only to
identify which genetic variants increase susceptibility to the disease
but also which environmental risk factors act in concert with these
genes. In addition, the cellular environment in men and woman
can be very different given known differences in hormonal milieu
and gene expression [3]. Therefore, it is reasonable to consider the
possibility that gender specific gene-environment interactions
could modify the penetrance and expression of the trait.
Muscle glycogen synthase is the key enzyme in the synthesis of
glycogen in skeletal muscle. A polymorphism (XbaI) in intron 14
of the glycogen synthase gene (GYS1) has been associated with
lower glycogen synthase activity, T2D, features of the metabolic
syndrome (MetS) and with myocardial infarction in males [4–8]
but association to T2D has not been consistently replicated in all
studies [9,10]. Interestingly, electrical stimulation of skeletal
muscle to mimic physical exercise increased the amount of
glycogen synthase in carriers of wild-type C-allele but not in
carriers of the T-allele. As a consequence, carriers of the T-allele
may benefit less from physical exercise than carriers of the normal
allele [11]. GYS1 is located on chromosome 19q13.3, a region that
has in several linkage studies been linked to MetS and T2D
associated phenotypes [12–17]. Further, the GYS1 locus was in the
HERITAGE family study linked to glucose effectiveness in
response to endurance exercise [18].
GYS1 is separated only by 4.1 million base pairs from the gene
coding for apolipoprotein E (APOE), which constitutes three
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common genetic isoforms in plasma and is known to play an
important role in lipid metabolism [19]. The APOE4 isoform
encoded by the e4 allele is associated with elevated serum total-
and low density lipoprotein (LDL)-cholesterol concentrations
[20,21] and with coronary heart disease (CHD) [22,23]. In addi-
tion, a –219 (G.T) polymorphism in the APOE promoter has in
vitro been shown to decrease transcriptional activity of APOE [24]
and has been reported to associate with severity of coronary artery
disease [25] and increased risk for myocardial infarction [26].
Given the considerations above, we set out to test 1) whether the
GYS1 polymorphism is associated with CV mortality in individuals
from a large T2D family study from Finland, the Botnia Study. In
particular we were interested in putative gender differences as the
GYS1 polymorphism has earlier been associated with myocardial
infarction only in males, 2) whether physical exercise would act as an
environmental factor interacting with the effect associated with the
GYS1 polymorphism as this has earlier been shown to be associated
with defect in stimulation of glycogen synthase protein levels after
muscle stimulation, and 3) to test if our results with the GYS1
polymorphismare independent of the adjacentAPOE. As the endpoint
we used CV mortality after a median follow up period of 8 years.
METHODS
Study Population
The Botnia Study was initiated in 1990 and represents a large
population-based family study in Finland and Sweden aiming at
identification of genes increasing susceptibility to T2D, MetS and
related disorders. Details of the study cohort, sampling strategy as
well as anthropometric and metabolic measurements have been
described in detail [27,28]. The study protocol was approved by
the local ethics committees and an informed consent was obtained
from each subject before participating in the study. The present
study was restricted to the original Botnia cohort of 4654 subjects
from 965 families (2142 males, 2512 females, age 58.2613.8 years)
from Western Finland. At the baseline examination, a structured
questionnaire was completed by specially trained nurses, covering
information about diseases other than T2D (particularly hyper-
tension, coronary heart disease, myocardial infarction and stroke)
and data on smoking habits and physical activity during work and
leisure time. Both previous and current smokers were recorded as
smokers. Physical activity level during work was defined on a scale
from 0 to 6 according to level of physical activity (0 coding for no
work and 6 for highest level) while physical activity during leisure
time was estimated by a scale from 1 to 3 (1 = almost no activity at
all; 2 = sometimes, but not regular; 3 = regular physical activity).
Information on work and leisure time physical activity was
combined to obtain an estimate of total physical activity level and
classified as: 1) no physical activity or low physical activity (work
level of 0 to 2 in combination of leisure time level of 1); 2) normal
to high physical activity (work activity level 0–2 in combination of
leisure time activity of .1; or work activity level $3 in combina-
tion of any leisure time activity level). When division between high
and normal physical activity was needed, normal physical activity
was defined as work activity level $3 and leisure time of ,3 and
high physical activity was defined as leisure time activity of 3 in
combination with any work activity level. Glucose tolerance,
assessed by an oral glucose tolerance test, and MetS were defined
according to current World Health Organization (WHO) criteria
[29]. Insulin resistance was estimated as the Homeostasis Model
Assessment index (HOMAIR= fasting serum insulin*fasting plas-
ma glucose/22.5).
Total and CV mortality was assessed with median follow up time
of 7.9 years and mortality data were obtained from central death-
certificate registry in Finland. CV mortality was classified using the
9th revision of the International Classification of Diseases (CV diag-
nosis codes 390–459) before 1997 and the 10th revision (codes 100–
199) thereafter. Causes of death were classified as 1) CV death
(CHD, cerebrovascular disease (including both thrombotic stroke
and cerebral haemorrhage) or other CV events (including pulmon-
ary embolism, abdominal aortic aneurysm, hypertensive complica-
tions, general atherosclerosis and peripheral artery disease with
gangrene) or 2) other causes of death (neoplasma, violent or other).
Genotyping
A total of 4654 subjects were genotyped for the XbaI poly-
morphism in intron 14 (rs8103451) of GYS1 and for the APOE
isoforms encoded by amino acid substitutions at residues 112
(rs429358) and 158 (rs7412), for the –219G.T promoter
polymorphism (rs405509). The XbaI polymorphism in GYS1 was
genotyped using single base pair extension on AB3100 (Applied
Biosystems) and the APOE polymorphisms were genotyped using
allelic discrimination on AB7900 at the SWEGENE DNA geno-
typing Laboratory. Before any analyses were performed, the
expected risk-genotypes for GYS1 and APOE were defined as CT
or TT (GYS1 XbaI), e3e4 or e4e4 (APOE codon 112 and 158 poly-
morphisms) and TT (APOE –219 polymorphism), respectively. Risk-
alleles were defined according to previous T2D andMetS association
study results for GYS1 XbaI [4,7,8] and reports on APOE and risk of
coronary disease [22,25,26]. To assure high quality of the produced
genotypes, a random sample of 17.8% of all GYS1 XbaI genotypes
were repeated using PCR and restriction fragment length poly-
morphism and the concordance rate was 99.9% [30].
Statistical Analysis
Allele- and genotype frequencies between groups were compared
by the x2 test or by Fisher’s exact test whereas multiple regression
was used to compare clinical variables between groups, adjusting
for age, sex and BMI. Hardy-Weinberg equilibrium (HWE) was
tested using exact test (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl)
with alpha level of ,0.05 for rejection. For the survival analyses
the data were treated as left truncated and right censored,
meaning that age was the basic time variable. Survival curves were
obtained with the Kaplan-Meier estimator, and nonparametric
two-sample tests for genetic effects were performed with the log-
rank test. Covariates from the baseline visit were used. Effects of
genetic and clinical variables on survival time were analysed with
uni- and multivariate Cox regression analyses, stratified for sex
and using a robust variance estimate to adjust for within family
dependence by treating each pedigree as an independent entity
when calculating the variance. The univariate analyses were
performed to obtain relevant set of variables for multivariate
analyses, therefore these p-values were not corrected for multiple
testing. The multivariate Cox models were obtained by stepwise
forward inclusion of the covariates and statistical significance of
the model was analysed using the Wald test. Individuals with
missing data for any of the covariates were excluded from the
analyses. Due to missing data on microalbuminuria (data missing
for 35%) this variable was not included in the multivariate analysis.
Multiple tests were performed within the study (2 genes with 3
polymorphic sites and subanalyses in males and females). Con-
cerning the XbaI polymorphism in males subanalyses were also
performed according to physical activity level (low or normal to
high). We did not correct for the number of analysed genes and
polymorphisms as this study was designed to test the hypothesis
that the T-allele of the GYS1 XbaI polymorphism could be
associated with CV mortality and as the APOE markers were
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studied to test if the GYS1 results are independent of the adjacent
APOE. For the gender-specific analyses and for the analyses in
individuals with different physical activity levels we report both
non-adjusted (p) and adjusted (pc) p-values. The gender-specific
analyses were multiplied with a factor of 3 (3 groups; all, males,
females) and the physical activity analyses with a factor of 6 (3
groups with either low or normal to high physical activity).
All statistical analyses were performed using Number Crunch-
ing Statistical Systems version 2004 (NCSS; Kaysville, Utah, USA)
or R (www.r-project.org). Two sided p-values of less than 0.05
were considered statistically significant. Estimates of linkage dis-
equilibrium were calculated using the Haploview program [31].
Power calculations were performed using the normal distributions
for the coefficient estimates in the Cox regression model [32].
RESULTS
Clinical and metabolic risk factors for CV mortality
During a median follow-up time of 7.9 years, 749 of the 4654
individuals (16.1%) had died and of them 409 (54.6%) due to CV
causes (Table 1). Total mortality was slightly higher among males
than among females (17.4 vs. 15.0%, p= 0.029), while frequency
of CV mortality did not significantly differ between males and
females (9.2 vs. 8.4%, p= 0.32). Subjects who died of CV causes
had lower high density lipoprotein (HDL) cholesterol levels
compared to both living subjects (p,0.0001) and individuals
who died of other than CV causes (p = 0.0009). They also had
higher triglyceride levels (p,0.0001) and higher frequency of T2D
(p,0.0001), MetS (p = 0.0002), hypertension (p= 0.015), micro-
albuminuria (p,0.0001), earlier CV events (,0.0001) and lower
physical activity level than subjects who were alive. CV death was
associated with higher BMI (p= 0.046), total cholesterol levels
(p = 0.0037), frequency of T2D (p,0.0001) and earlier CV events
(p,0.0001) than death of other causes (Table 1).
Male gender, abdominal obesity, dyslipidaemia, T2D, hyper-
tension, microalbuminuria, earlier CV events, smoking and low
physical activity level were significant predictors of CV mortality
among all individuals in univariate Cox regression analyses
(Table 2). Gender specific univariate analyses identified low
HDL cholesterol, T2D, hypertension, microalbuminuria, earlier
CV events and physical inactivity as significant risk factors in both
genders. Smoking was a significant risk factor only among male
subjects while abdominal obesity and elevated triglyceride levels
were significant predictors of CV death only in females (Table 2).
In multivariate analyses T2D, elevated fasting insulin concen-
tration, earlier CV events, low physical activity and smoking were
significant risk factors for CV mortality in males (model 1 in
Table 3). In females T2D, high fasting glucose concentration,
hypertension, earlier CV events, and physical inactivity were
significant risk factors for CV mortality (model 1 in Table 4). Due
to lack of data for a large part (35%) of the study subjects,
microalbuminuria was not included in the multivariate model.
Allelic association between the GYS1 and APOE
polymorphisms
Genotype frequencies of the GYS1 XbaI polymorphisms and
APOE in the study population were: GYS1 XbaI C/T (CC 88.0%,
CT 11.5%, TT 0.6%), APOE –219G.T (GG 29.5%, GT 50.2%,
TT 20.3%), and APOE e2/e3/e4 (e2e2 0.4%, e2e3 9.4%, e2e4
2.3%, e3e3 59.4%, e3e4 25.2%, e4e4 3.2%). The genotypes of all
single nucleotide polymorphisms (SNPs) (APOE Cys112Arg,
Arg158Cys, -219G.T and GYS1 XbaI) and the relative
frequencies of e-alleles, were in Hardy Weinberg equilibrium in
the whole study population. Neither the genotype frequencies nor
their combinations differed between males and females. The APOE
–219G.T and Arg158Cys as well as the Arg158Cys and
Cys112Arg polymorphisms were in complete linkage disequilibri-
um (D9=1.0). The GYS1 XbaI polymorphism was not in linkage
disequilibrium with any of the three APOE SNPs (r2 = 0.0, for all
and D9=0.12, 0.07 and 0.16, for APOE-219G.T, Cys112Arg
and Arg158Cys, respectively).
GYS1 XbaI as a genetic predictor for CV mortality
The frequency of the XbaI risk genotypes (CT or TT) did not
significantly differ between patients who died of CV causes, other
causes or survivors when all subjects were included in the analyses
(13.3%, 10.5%, and 12.0%) (Table 5). However, in gender-specific
analyses, males with CV death had more often the CT/TT geno-
TABLE 1. CHARACTERISTICS OF THE STUDY SUBJECTS
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CHARACTERISTIC ALL SUBJECTS ALIVE CV DEATH OTHER DEATH
N (males/females) 4654 (2142/2512) 3905 (1770/2135) 409 (198/211) 340 (174/166)
Age (years) 58.2613.8 55.3612.5 75.069.1 71.6611.0
BMI (kg/m2) 26.864.4 26.864.4 27.364.4 26.864.2
WH -males 0.9660.06 0.9660.06 0.9760.07 0.9760.07
-females 0.8560.08 0.8560.08 0.8960.08 0.8760.06
Cholesterol (mmol/l) 5.861.1 5.861.1 5.961.3 5.761.2
HDL cholesterol (mmol/l) 1.360.3 1.360.3 1.260.3 1.360.3
Triglycerides (mmol/l) 1.561.1 1.561.0 2.061.2 1.861.5
Type 2 diabetes (%) 34.3 27.5 78.6 60.3
Metabolic syndrome (%) 40.7 37.0 62.2 54.8
Hypertension (%) 47.2 43.2 71.9 64.1
Microalbuminuria (%) 7.7 6.1 22.8 15.8
Earlier CV events (%) 18.4 14.3 51.3 27.4
Smoking (%) 38.6 38.6 36.5 40.3
Low physical activity (%) 12.9 8.0 45.2 33.1
BMI; body mass index, WH; waist to hip ratio
doi:10.1371/journal.pone.0000285.t001..
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types compared to surviving males (19.2 vs. 11.8%, p= 0.0038,
pc = 0.011). Consequently, in the Cox regression analysis, the
GYS1 XbaI CT/TT genotypes were significant predictors of CV
mortality in males (Table 2 and Figure 1A). The CT/TT
genotypes did not predict mortality due to other than CV causes.
Furthermore, when analysed together the GYS1 XbaI poly-
morphism, T2D, earlier CV events, low physical activity and
smoking were significant risk factors for CV mortality in males
(model 2 in table 3).
Does physical activity influence the effect
associated with the genetic variation in GYS1 on CV
mortality risk?
CV mortality was significantly higher among individuals with low
physical activity level compared to individuals with normal (29.9
vs. 7.1%, p,0.0001, corrected for sex and age) or high (29.9 vs.
5.7%, p,0.0001) physical activity level. The difference was not
significant between groups reporting normal or high physical
activity level (7.1 vs. 5.4%, p= 0.35) suggesting minimal or no
protective effect above a normal level of physical activity on CV
mortality risk. In a multivariate Cox regression analysis both
physical activity (hazard ratio (HR) 3.2 [2.2–4.6], p,0.0001,
pc,0.0001) and the XbaI polymorphism (HR 2.6 [1.7–3.8],
p,0.0001, pc,0.0001) were strongly associated with CV mortal-
ity. While physical activity itself (normal or high) had a strong
protective effect on CV mortality, this effect was attenuated in
carriers of the CT/TT-genotypes of the XbaI polymorphism;
physically active males with the CT/TT genotypes had a 2.7-times
higher risk for CV mortality compared to CC-genotype carriers
(HR 2.7 [1.8–4.1], p,0.0001, pc,0.0001) (Figure 2).
APOE polymorphisms as genetic predictors for CV
mortality
The frequency of the APOE e2/e3/e4 risk genotypes (e3e4 or e4e4),
the APOE –219 risk genotype (TT) or the risk genotype
combination of APOEe and APOE –219 (-219TT/e4) did not
TABLE 2. CLINICAL AND GENETIC RISK FACTORS FOR CV MORTALITY
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ALL INDIVIDUALS MALE SUBJECTS FEMALE SUBJECTS
HR [95% CI] P HR [95% CI] p HR [95% CI] p
Male sex 1.6 [1.3–1.9] ,0.0001
BMI (kg/m2) 1.0 [1.0–1.0] 0.060 1.0 [1.0–1.1] 0.14 1.0 [1.0–1.1] 0.078
WH 27.6 [7.9–96.5] ,0.0001 3.7 [0.2–73.1] 0.39 18.8 [3.2–111.4] 0.0012
Cholesterol (mmol/l) 1.0 [0.9–1.1] 0.52 1.0 [0.9–1.2] 0.76 1.0 [0.9–1.2] 0.88
HDL-cholesterol (mmol/l) 3.1 [2.0–4.1] ,0.0001 2.5 [1.3–4.8] 0.0049 2.7 [1.7–4.1] ,0.0001
Triglycerides (mmol/l) 1.1 [1.1–1.2] 0.0017 1.1 [1.0–1.2] 0.16 1.4 [1.2–1.5] ,0.0001
Type 2 diabetes 3.2 [2.5–4.2] ,0.0001 3.2 [2.3–4.6] ,0.0001 3.2 [2.2–4.8] ,0.0001
Metabolic syndrome 1.3 [1.0–1.5] 0.030 1.3 [1.0–1.7] 0.10 1.2 [0.9–1.6] 0.25
Hypertension 1.4 [1.1–1.7] 0.0046 1.4 [1.1–1.9] 0.021 1.4 [1.0–2.0] 0.036
Microalbuminuria 2.3 [1.6–3.3] ,0.0001 2.1 [1.3–3.3] 0.0014 2.3 [1.4–4.1] 0.0022
Earlier CV events 2.5 [2.0–3.0] ,0.0001 2.8 [2.0–3.7] ,0.0001 2.1 [1.6–2.8] ,0.0001
Smoking 1.7 [1.3–2.1] ,0.0001 1.5 [1.1–2.1] 0.0075 1.1 [0.5–2.2] 0.83
Low physical activity 2.6 [2.0–3.3] ,0.0001 2.9 [2.1–4.0] ,0.0001 2.6 [1.9–3.6] ,0.0001
APOE E3E4/E4E4 1.1 [0.9–1.4] 0.31 0.9 [0.6–1.2] 0.43 1.4 [1.0–1.9] 0.030
APOE –219 TT 1.1 [0.9–1.4] 0.32 0.8 [0.5–1.1] 0.19 1.5 [1.1–2.1] 0.0082
APOE risk genotype combination 1.3 [1.0–1.8] 0.064 0.6 [0.3–1.2] 0.14 2.3 [1.6–3.2] ,0.0001
GYS1 XbaI CT/TT 1.2 [0.9–1.6] 0.24 1.8 [1.2–2.6] 0.0016 0.7 [0.4–1.2] 0.18
Univariate Cox proportional-hazards analysis, performed with robust variance estimate to adjust for within family dependence. BMI; body mass index, WH; waist to hip
ratio
doi:10.1371/journal.pone.0000285.t002..
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TABLE 3. MULTIVARIATE MODEL OF RISK FACTORS FOR CV MORTALITY IN MALES
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
RISK PHENO-/GENOTYPE MODEL 1 CLINICAL VARIABELES P MODEL 2 CLINICAL AND GENETIC VARIABLES P
GYS1 XbaI (T) 1.9 [1.2–2.9] 3.5e23 *
T2D 2.4 [1.6–3.7] 3.0e25 2.5 [1.7–3.8] 1.2e25
Fasting serum insulin 1.0 [1.0–1.0] 3.5e22
Earlier CV events 1.9 [1.4–2.7] 2.1e24 1.7 [1.2–2.5] 6.0e23
Low physical activity 1.9 [1.3–2.8] 1.7e23 1.9[1.2–2.9] 3.1e23
Smoking 1.6 [1.0–2.3] 3.4e22 1.5 [1.0–2.3] 3.2e22
P-value (model, Wald test) 3.9e214 7.0e211
Multivariate Cox regression analysis using stepwise forward inclusion with robust variance estimates. Adjusted for age, sex and family correlations. * Pc = 0.018
doi:10.1371/journal.pone.0000285.t003..
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TABLE 4. MULTIVARIATE MODEL OF RISK FACTORS FOR CV MORTALITY IN FEMALES
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
RISK PHENO-/GENOTYPE MODEL 1 CLINICAL VARIABELES P MODEL 2 CLINICAL AND GENETIC VARIABLES P
APOE (E3E4/E4E4 and –219 TT) 2.9 [1.9–4.4] 2.6e26 *
T2D 1.7 [1.0–2.9] 3.9e22
Fasting plasma glucose 1.1 [1.1–1.2] 1.3e25 1.2 [1.1–1.2] 2.3e210
BMI 1.0 [1.0–1.1] 2.2e22
Hypertension 1.6 [1.1–2.4] 2.9e22 1.9 [1.2–3.1] 7.3e23
Earlier CV events 1.6 [1.1–2.3] 1.2e22 1.9 [1.3–2.8] 5.9e24
Low physical activity 2.1 [1.4–3.1] 2.5e24 1.9 [1.2–2.8] 4.9e23
P-value (model, Wald test) 5.4e214 ,1.0e210
Multivariate Cox regression analysis using stepwise forward inclusion with robust variance estimates. Adjusted for age, sex and family correlations. * Pc = 7.8e
26
doi:10.1371/journal.pone.0000285.t004..
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Figure 1. CV mortality in males and females according to the GYS1 XbaI (A) and APOE –219/e2/e3/e4 (B) genotypes. Kaplan Meier survival curves
illustrating a higher risk for CV mortality (HR 1.8 [1.2–2.6], p = 0.0016, pc = 0.0096) in male carriers of the GYS1 XbaI CT/TT-genotypes and in female
carriers of the APOE –219TT/e4 genotype combination (HR 2.3 [1.6–3.2], p,0.0001, pc,0.0001).
doi:10.1371/journal.pone.0000285.g001
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significantly differ between individuals who died of CV causes and
other subjects (Table 5). However, females in the CV mortality
group had more often the APOE –219 TT-genotype, in particular -
219TT/e4 compared to surviving females (26.9 vs. 19.8%, p=
0.019, pc = 0.057 and 17.5 vs. 9.4%, p= 0.00048, pc = 0.0014). No
effect of the APOE variants was observed in males, this effect being
restricted to females in whom both the APOE e4-allele, the –219
TT-genotype and their combination were significant predictors of
CV mortality (Table 2 and Figure 1B), but not of non-CV
mortality. When genetic and non-genetic factors were included in
the analysis of risk of CV death, the APOE risk genotype
combination, high fasting glucose level, high BMI, hypertension,
earlier CV events and low physical activity were significant risk
factors for CV mortality in females (model 2 in table 4).
Cholesterol levels and CV mortality according to
APOE e3e4/e4e4 and -219 TT genotypes
The APOE e3e4/e4e4 and -219 TT genotypes (and their combi-
nation) were associated with increased total and LDL cholesterol
levels in both males and females (after adjustment for age, T2D
and BMI). Interestingly, although the APOE e3e4/e4e4 variants
had a statistically weaker effect on total cholesterol in female
carriers (6.161.2 vs. 5.861.2 mmol/l, p = 0.014, pc = 0.084 for
the e3e4/e4e4 genotype vs. other genotypes) compared to non-
carriers (6.161.2 vs. 5.861.1 mmol/l, p = 0.0001 pc = 0.0006) of
APOE -219 TT, they only predicted CV mortality in carriers of
APOE -219 TT (HR 2.3, [1.3–4.2], p = 0.0059, pc = 0.035). The -
219 polymorphism had no effect on cholesterol levels neither in
female carriers nor non-carriers of the APOE e3e4/e4e4, and
predicted CV mortality only in carriers of the APOE e3e4/e4e4
genotypes (HR 2.3 [1.5–3.6], p = 0.00038, pc = 0.0023).
In males, the APOE e3e4/e4e4 genotypes affected total choles-
terol in carriers (5.961.0 vs. 5.661.2 mmol/l, p = 0.031, for the
e3e4/e4e4 genotype vs. other genotypes, respectively) but not after
correcting for multiple testing (pc = 0.19) and not in non-carriers
(5.761.0 vs. 5.661.1 mmol/l, p = 0.31) of the APOE -219 TT
genotype. As in females, the APOE -219 TT genotype had no
significant effect on cholesterol values neither in carriers nor in
non-carriers of the APOE e3e4/e4e4 genotypes. In contrast to
females, neither APOE e3e4/e4e4 nor APOE -219 TT predicted
CV mortality in males.
Independency between GYS1 and APOE as risk
factors for CV mortality
To investigate whether the ‘at-risk’ genotypes of GYS1 and APOE
contributed independently to the CV mortality risk, we performed
Cox regression analyses by entering both genes into the equation.
These analyses clearly indicated that the effect of GYS1 XbaI CT/
TT in males (XbaI CT/TT: HR 1.9 [1.3–2.7], APOE –219/e4:
HR 1.5 [0.9–2.5]), as well as the effect of APOE genotype
combination in females (APOE –219/e4: HR 2.4 [1.7–3.6], GYS1
XbaI CT/TT: HR 1.3 [0.8–2.3]), were independent of each
TABLE 5. GENOTYPE DISTRIBUTION IN SUBJECTS WHO DIED FROM CV CAUSES AND IN SUBJECTS WHO ARE ALIVE OR DIED DUE TO
OTHER CAUSES
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GENE AND RISK GENOTYPE CV DEATH OTHER SUBJECTS
All subjects (N = 4654) Percent
APOE e2/e3/e4 E3E4/E4E4 27.2 28.6
APOE -219 TT 23.1 20.1
APOE e2/e3/e4/-219 risk genotype combination 12.8 10.2
GYS1 Xba1 CT/TT 13.3 11.9
Males (N = 2142)
APOE e2/e3/e4 E3E4/E4E4 22.7 29.1
APOE -219 TT 19.1 20.8
APOE e2/e3/e4/-219 risk genotype combination 7.7 11.2
GYS1 Xba1 CT/TT 19.1{ 11.8
Females (N = 2512)
APOE e2/e3/e4 E3E4/E4E4 31.4 28.2
APOE -219 TT 26.9* 19.5
APOE e2/e3/e4/-219 risk genotype combination 17.5{ 9.4
GYS1 Xba1 CT/TT 7.9 12.0
Fischer’s exact test, *p = 0.019 (pc = 0.057), {p = 0.0038 (pc = 0.011), {p = 0.00048 (pc = 0.0014)
doi:10.1371/journal.pone.0000285.t005..
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Figure 2. Interaction between the GYS1 XbaI polymorphism and
physical activity (PA) in males. Kaplan Meier survival curves for males
reporting normal to high physical activity (PA) level according to GYS1
XbaI genotype compared to males with low PA level.
doi:10.1371/journal.pone.0000285.g002
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other. To further assess the independence of the effects of the
polymorphisms on CV mortality, the samples were stratified
according to GYS1 and APOE genotypes: The XbaI T-allele was
associated with CV mortality in males without the APOE risk
genotype combination (HR 1.9 [1.3–2.8]) and the APOE risk-
genotype combination was associated with cardiovascular mortal-
ity among female XbaI CC-carriers (HR 2.3 [1.6–3.5]).
DISCUSSION
The key findings of the present study were that 1) the XbaI
polymorphism in GYS1 was associated with CV mortality in males;
2) although physical activity markedly reduces risk of CV death,
this protective effect was attenuated in male carriers of the XbaI
polymorphism; and 3) despite the fact that GYS1 is adjacent to
APOE on chromosome 19q13, the effect of the GYS1 polymorphism
on CV mortality is independent of the effect of APOE, which exerts
a strong effect on CV mortality risk by its own. Interestingly, this
risk seems to be restricted to females and cannot fully be explained
by the effect of the APOE alleles on cholesterol levels.
Several studies performed in different ethnic populations have
reported linkage to chromosome 19q13 for LDL-cholesterol- [33–
37] or triglyceride levels [38], obesity [39,40], as well as for insulin
resistance and T2D related phenotypes [12–17] but the underlying
genetic variants have not been identified. In addition, glucose
effectiveness in response to exercise training as well as significant
sex specific differences in heritability models and sex interaction
for HDL cholesterol have been mapped to the 19q13 region
[18,41]. We therefore set out to study the contribution of two
candidate genes in this region, GYS1 and APOE to CV mortality
risk, focusing particularly on the role of putative interaction
between GYS1 polymorphism and gender and/or physical activity
level to affect the CV mortality rate.
The GYS1 XbaI polymorphism was significantly associated with
increased risk for CV mortality in males, a result supported by our
previous independent finding of an association between myocar-
dial infarction and this particular polymorphism only in males in
another study population [7].
As anticipated, a low physical activity level was a severe risk
factor for CV mortality. The novel finding of our study was that
the protective effect of physical exercise was attenuated in carriers
of the XbaI polymorphism. This goes along with the hypothesis
advanced by a Canadian study [11] that carriers of the risk T-
allele have a defect in their ability to increase the glycogen
synthase protein in response to neuromuscular electrical stimula-
tion (as a proxy for physical exercise) [11]. An increase in glycogen
synthase protein would promote glycogen formation which, in
turn, could have a beneficial effect on exercise capacity. The
downside of this message is that all individuals would not respond
to physical exercise in the same way. The positive message is that
the ‘‘non-responder’’ group is relatively small (frequency of CT/
TT genotypes in the population is only 12%) and in 88% of the
population exercise exerts a highly beneficial and protective effect
on risk of CVD.
We have no apparent explanation for why the effect of the XbaI
polymorphism was restricted to males. One potential explanation
could be that women have less muscle mass and muscular strength
than men, but also a tendency to metabolise fat rather than
carbohydrate during exercise [42]. Moreover, women seem less
vulnerable to exercise-induced sudden death [42]. A potential
explanation could be that both exercise training and oestrogen
increase Akt phosphorylation and glycogen synthase kinase-3
inactivation leading to increased glycogen synthase activity.
Interestingly, markedly higher myocardial Akt nuclear activity
has been reported in females than in males as well as in pre-
compared to post-menopausal woman [43]. If this also applies to
skeletal muscle it could provide a potential explanation for the
observed gender-specific effect.
Our results are in agreement with the earlier results reporting
either the APOE e4-allele or the APOE -219 TT-genotype as risk
factors for CVD and/or mortality [22,23,25,26] but, interestingly,
we could observe this effect only in females. Caution is, however,
warranted in the interpretation of the gender-specific effects of
APOE as the study included a large number of patients with T2D.
It is known, that men with T2D have an excess mortality
compared with women with T2D resulting in a relative increase in
the frequency of female T2D patients with aging. It is therefore
still possible that the APOE polymorphisms had an effect in male
T2D resulting in premature death. A sub-analysis of men and
women divided by the median of age did, however, not support
such an explanation. Also, power is reduced when the analysis is
restricted to gender. The power in a Cox regression analysis
depends among other things on the accrual time during which
patients are recruited, mean time to failure and the expected
effect sizes (http://biostat.mc.vanderbilt.edu/twiki/bin/view/
Main/PowerSampleSize)[44]. We used the standard Normal
theory to calculate the power to detect a HR of a certain size
[32]. Our study had a 73–96% power to detect hazard ratios of 1.5
for the analysed polymorphisms.
In conclusion, we demonstrate a protective effect of physical
activity on CV mortality. However, in male subjects this effect was
attenuated in carriers of the rare allele of the XbaI polymorphism
in GYS1. This finding could be compatible with a previous demon-
stration of defective increase in the glycogen synthase protein in
carriers of this polymorphism. We could exclude that the
association between the GYS1 polymorphism and CV mortality
was due to the adjacent APOE gene. Instead, we demonstrated that
this gene exerted an increased risk of CV mortality in females.
These findings re-emphasize the need to consider the effect of
genetic variants in complex diseases in concert with their
environmental triggers but also to evaluate whether females and
males respond differently to genes and the environment.
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